ASCO 2021: Extended Bevacizumab Treatment Fails to Improve Outcomes in Advanced Ovarian Cancer
Bevacizumab treatment duration of 15 months remains the standard of care
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.